- HK$20.27bn
- HK$10.47bn
- $630.20m
- 15
- 39
- 35
- 15
RCS - Hutchmed China Ltd - Positive Topline Results of Phase III Trial
AnnouncementRCS - Hutchmed China Ltd - Surufatinib + Camrelizumab PDAC Phase 3 initiation
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - China NDA Acceptance-Savolitinib in Gastric Cancer
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - NDA Acceptance in China for Fanregratinib
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Development of ATTC Candidate
AnnouncementREG - Hutchmed China Ltd - Expanded NRDL Coverage + CIDL Inclusion in China
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data at ESMO and ASH
AnnouncementRCS - Hutchmed China Ltd - Enrollment Complete in SAFFRON Global Phase III
AnnouncementRCS - Hutchmed China Ltd - Updates from R&D Event
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Presents Data at AACR NCI EORTC
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at the 2025 ESMO Congress
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ESMO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present R&D Updates on October 31 2025
Announcement